📰 Pre Clinical Development News
Pre Clinical Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pre Clinical Development. Real-time updates on events, politics, business and more.
January 2, 2024
The gene therapy developer would provide Novartis access to its RNA-based screening platform — which helps in rapid discovery of experimental gene therapies — and would also be eligible for tiered royalties on global sales of products developed using the platform. The companies would collaborate to develop a pre-clinical gene therapy candidate for Huntington's disease (HD), an inherited condition that causes nerve cells in parts of the brain to gradually break down and die. ...
June 10, 2023
Transforming treatment outcomes for cancer patients BIO June 2023 Dr. Fiona McLaughlin, Chief Scientific Officer ... | June 10, 2023
May 15, 2023
Acesion Pharma has announced positive data from pre-clinical studies with AP31969, developed for chronic oral maintenance treatment to prevent atrial fibrillation (AF) recurrence.
March 24, 2023
/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," "we," or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve...
January 31, 2023
Learn how drug discovery experts are using protein biomarkers across different stages of the drug development process
February 8, 2022
/PRNewswire/ -- Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across...
January 20, 2022
Products, services, reviews and techniques used in lead molecule delivery, formulation and toxicology, using assays and animal models.
November 25, 2021
Pharmaceutical and biotechnology company Pfizer has sued a former employee for breaching her confidentiality agreement when she allegedly downloaded thousands ...
May 26, 2021
New appointments strengthen neuroscience-focused Scientific Advisory Board NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the appointment of Joy A. Cavagnaro, Ph.D., and Bruce A. Sullenger, Ph.D. to its Scientific Advisory Board. “Ovid is building the intellectual and scientific platform to tackle the big quest...